IKKα Antibody [B4D5]

Catalog No.: F5071

Application: Reactivity: Human, Mouse, Rat

Lane 1: HCT116, Lane 2: Daudi, Lane 3: A549, Lane 4: A20

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:200

Application
WB, IP

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Mouse, Rat

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
85 kDa

Datasheet & SDS

生物学的記述

Specificity
IKKα Antibody [B4D5] detects endogenous levels of total IKKα protein.

Clone
B4D5

Synonym(s)
Inhibitor of nuclear factor kappa-B kinase subunit alpha; I-kappa-B kinase 1; IKK-A; IKK-alpha; IkappaB kinase alpha; IKK1; Conserved helix-loop-helix ubiquitous kinase; Nuclear factor NF-kappa-B inhibitor kinase alpha; NFKBIKA; CHUK; IKKA

Background
IKKα constitutes one of the two catalytic subunits of the IκB kinase complex, alongside IKKβ, with NEMO serving as the regulatory scaffold in the canonical NF-κB pathway. The protein possesses an N-terminal kinase domain, a central ubiquitin-binding leucine zipper motif, and a C-terminal helix-loop-helix domain that mediates dimerization and complex assembly. Activation occurs through phosphorylation at serines within the activation loop by upstream kinases such as NIK and TAK1, inducing conformational shifts that enable substrate access and trans-autophosphorylation. IKKα phosphorylates IκBα at serines 32 and 36, marking it for K48-linked ubiquitination and proteasomal degradation, thereby liberating NF-κB dimers for nuclear translocation and transcription of genes involved in inflammation, survival, and proliferation. In the non-canonical pathway, NIK stabilizes and activates dimeric IKKα, which phosphorylates p100/RelB precursors to trigger their processing into p52/RelB, driving lymphoid organogenesis and B cell survival. IKKα interacts with RIP1, TRAF2/3, and TAX1BP1 to fine-tune signaling duration via negative feedback, including A20-mediated deubiquitination of adaptors. Beyond NF-κB, IKKα phosphorylates histone H3, Raptor, and TSC1 to integrate metabolic control with cytokine responses in keratinocytes and fibroblasts. Dimerization with IKKβ amplifies IκBα turnover under TNF stimulation, while NEMO polyubiquitination recruits IKKα to signaling platforms at receptor complexes. Dysregulation through amplification or constitutive activation promotes chronic inflammation, squamous cell carcinoma, and rheumatoid arthritis progression.

Background

IKKα constitutes one of the two catalytic subunits of the IκB kinase complex, alongside IKKβ, with NEMO serving as the regulatory scaffold in the canonical NF-κB pathway. The protein possesses an N-terminal kinase domain, a central ubiquitin-binding leucine zipper motif, and a C-terminal helix-loop-helix domain that mediates dimerization and complex assembly. Activation occurs through phosphorylation at serines within the activation loop by upstream kinases such as NIK and TAK1, inducing conformational shifts that enable substrate access and trans-autophosphorylation. IKKα phosphorylates IκBα at serines 32 and 36, marking it for K48-linked ubiquitination and proteasomal degradation, thereby liberating NF-κB dimers for nuclear translocation and transcription of genes involved in inflammation, survival, and proliferation. In the non-canonical pathway, NIK stabilizes and activates dimeric IKKα, which phosphorylates p100/RelB precursors to trigger their processing into p52/RelB, driving lymphoid organogenesis and B cell survival. IKKα interacts with RIP1, TRAF2/3, and TAX1BP1 to fine-tune signaling duration via negative feedback, including A20-mediated deubiquitination of adaptors. Beyond NF-κB, IKKα phosphorylates histone H3, Raptor, and TSC1 to integrate metabolic control with cytokine responses in keratinocytes and fibroblasts. Dimerization with IKKβ amplifies IκBα turnover under TNF stimulation, while NEMO polyubiquitination recruits IKKα to signaling platforms at receptor complexes. Dysregulation through amplification or constitutive activation promotes chronic inflammation, squamous cell carcinoma, and rheumatoid arthritis progression.

References
[1] Yamamoto Y, et al. Mol Cell Biol. 2000 May;20(10):3655-66. [2] Solt LA, et al. Immunol Res. 2008;42(1-3):3-18.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%